Suppr超能文献

相似文献

1
Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.
Oncoimmunology. 2017 Nov 27;7(2):e1364827. doi: 10.1080/2162402X.2017.1364827. eCollection 2018.
6
Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Cancer Res. 2009 Oct 1;69(19):7775-83. doi: 10.1158/0008-5472.CAN-09-2123. Epub 2009 Sep 8.
8
NKG2D and MICA/B shedding: a 'tag game' between NK cells and malignant cells.
Clin Transl Immunology. 2020 Dec 22;9(12):e1230. doi: 10.1002/cti2.1230. eCollection 2020.
9
Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
J Immunol. 2012 Aug 1;189(3):1360-71. doi: 10.4049/jimmunol.1200796. Epub 2012 Jun 22.
10
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Brain. 2006 Sep;129(Pt 9):2416-25. doi: 10.1093/brain/awl205. Epub 2006 Aug 3.

引用本文的文献

1
Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities.
Exp Hematol Oncol. 2025 Jun 13;14(1):83. doi: 10.1186/s40164-025-00676-x.
2
Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer.
Cancers (Basel). 2025 May 17;17(10):1689. doi: 10.3390/cancers17101689.
3
CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges.
Front Immunol. 2024 Nov 6;15:1489649. doi: 10.3389/fimmu.2024.1489649. eCollection 2024.
5
Platelet and epithelial cell interations can be modeled in cell culture, and are not affected by dihomo-gamma-linolenic acid.
PLoS One. 2024 Aug 27;19(8):e0309125. doi: 10.1371/journal.pone.0309125. eCollection 2024.
7
In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors.
Oncoimmunology. 2024 Jul 18;13(1):2379062. doi: 10.1080/2162402X.2024.2379062. eCollection 2024.
8
A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers.
Int J Mol Sci. 2024 Jun 15;25(12):6595. doi: 10.3390/ijms25126595.
9
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Cells. 2024 Apr 23;13(9):726. doi: 10.3390/cells13090726.
10
Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME).
Heliyon. 2024 Mar 3;10(5):e27480. doi: 10.1016/j.heliyon.2024.e27480. eCollection 2024 Mar 15.

本文引用的文献

1
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
Leukemia. 2017 Feb;31(2):459-469. doi: 10.1038/leu.2016.194. Epub 2016 Jul 20.
2
Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.
Science. 2015 Apr 3;348(6230):136-9. doi: 10.1126/science.1258867. Epub 2015 Mar 5.
4
Paraneoplastic thrombocytosis: the secrets of tumor self-promotion.
Blood. 2014 Jul 10;124(2):184-7. doi: 10.1182/blood-2014-03-562538. Epub 2014 May 27.
5
Molecular Bases for the Regulation of NKG2D Ligands in Cancer.
Front Immunol. 2014 Mar 21;5:106. doi: 10.3389/fimmu.2014.00106. eCollection 2014.
6
New prospects on the NKG2D/NKG2DL system for oncology.
Oncoimmunology. 2013 Oct 1;2(10):e26097. doi: 10.4161/onci.26097. Epub 2013 Oct 25.
7
A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.
Neuro Oncol. 2014 Mar;16(3):382-91. doi: 10.1093/neuonc/not232. Epub 2013 Dec 9.
9
Regulation of ligands for the NKG2D activating receptor.
Annu Rev Immunol. 2013;31:413-41. doi: 10.1146/annurev-immunol-032712-095951. Epub 2013 Jan 3.
10
RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry.
J Exp Med. 2012 Dec 17;209(13):2409-22. doi: 10.1084/jem.20120565. Epub 2012 Nov 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验